Ginkgolide With Intravenous Alteplase Thrombolysis in Acute Ischemic Stroke Improving Neurological Function: A Multicenter, Cluster-Randomized Trial (GIANT)

Background and Purpose: We aimed to investigate the effect of Ginkgolide® treatment on neurological function in patients receiving intravenous (IV) recombinant tissue plasminogen activator (rt-PA). Methods: This cluster randomized controlled trial included acute ischemic stroke patients in 24 centers randomized to intervention of intravenous Ginkgolide® or control group within the first 24 h after IV rt-PA therapy (IVT). Clinical outcome at 90 days was assessed with modified Rankin Scale (mRS) score and dichotomized into good outcome (0–2) and poor outcome (3–6). Hemorrhagic transformation represented the conversion of a bland infarction into an area of hemorrhage by computed tomography. Symptomatic intracerebral hemorrhage (sICH) was defined as cerebral hemorrhagic transformation in combination with clinical deterioration of National Institutes of Health Stroke Scale (NIHSS) score ≥4 points at 7-day or if the hemorrhage was likely to be the cause of the clinical deterioration. We performed logistic regression analysis and propensity score matching analysis to investigate the impact of Ginkgolide® treatment with IV rt-PA on good outcome, hemorrhagic transformation and sICH, respectively. Results: A total of 1113 patients were finally included and 513 (46.1%) were in the intervention group. Patients in the Ginkgolide® group were more likely to have good outcomes (78.6 vs. 66.7%, p < 0.01) and lower rate of sICH (0 vs. 2.72%, p < 0.01), compared with patients in the control group. The intra-cluster correlation coefficient (ICC) for good outcome at 90 days was 0.033. Binary logistic regression analysis revealed that treatment with Ginkgolide® was independently associated with 90-day mRS in patients with IV rt-PA therapy (OR 1.498; 95% CI 1.006–2.029, p = 0.009). After propensity score matching, conditional logistic regression showed intervention with Ginkgolide® was significantly associated with 90-day good outcome (OR 1.513; 95% CI 1.073–2.132, p = 0.018). No significant difference in hemorrhage transformation was seen between the 2 matched cohorts (OR 0.885; 95% CI 0.450–1.741, p = 0.724). Conclusion: Using Ginkgolide® within 24-hour after IV rt-PA is effective and safe and might be recommended in combination with rtPA therapy in acute ischemic stroke. Clinical Trial Registration: http://www.clinicaltrials.gov, identifier NCT03772847.

Background and Purpose: We aimed to investigate the effect of Ginkgolide ® treatment on neurological function in patients receiving intravenous (IV) recombinant tissue plasminogen activator (rt-PA).
Methods: This cluster randomized controlled trial included acute ischemic stroke patients in 24 centers randomized to intervention of intravenous Ginkgolide ® or control group within the first 24 h after IV rt-PA therapy (IVT). Clinical outcome at 90 days was assessed with modified Rankin Scale (mRS) score and dichotomized into good outcome (0-2) and poor outcome (3-6). Hemorrhagic transformation represented the conversion of a bland infarction into an area of hemorrhage by computed tomography. Symptomatic intracerebral hemorrhage (sICH) was defined as cerebral hemorrhagic transformation in combination with clinical deterioration of National Institutes of Health Stroke Scale (NIHSS) score ≥4 points at 7-day or if the hemorrhage was likely to be the cause of the clinical deterioration. We performed logistic regression analysis and propensity score matching analysis to investigate the impact of Ginkgolide ® treatment with IV rt-PA on good outcome, hemorrhagic transformation and sICH, respectively.
Results: A total of 1113 patients were finally included and 513 (46.1%) were in the intervention group. Patients in the Ginkgolide ® group were more likely to have good outcomes (78.6 vs. 66.7%, p < 0.01) and lower rate of sICH (0 vs. 2.72%, p < 0.01), compared with patients in the control group. The intra-cluster correlation coefficient (ICC) for good outcome at 90 days was 0.033. Binary logistic regression analysis revealed that

INTRODUCTION
Intravenous recombinant tissue plasminogen activator (rt-PA) administered within 4.5 h of onset (or later if a favorable perfusion imaging profile is present) could improve neurological outcome in patients with acute ischemic stroke (AIS). Treatments for AIS continue to evolve after the superior value of endovascular thrombectomy was confirmed over systemic thrombolysis. Unfortunately, up to 50% of such patients with successful recanalization still have an unfavorable outcome (Hussein et al., 2018), and numerous neuroprotective drugs have failed to show benefit in the treatment of AIS (Zhao et al., 2020). New methods to enhance the general efficacy of intravenous thrombolysis (IVT) are imperative in patients with AIS (Knecht et al., 2018).
The core problem in acute stroke is the loss of neuronal cells which makes recovery difficult or even not possible in the late states. Several key players in neuronal cell death within the penumbra have been identified, including excitotoxicity, oxidative stress, and inflammation. Oxidative stress directly leads to DNA damage that occurs within minutes after cerebral ischemic strokes (Li et al., 2018). Reperfusion therapy accompanying re-entry of oxygen and glucose into the ischemic brain fuels an excess production of reactive oxygen species (ROS) that overwhelms endogenous antioxidant reserves and leads to reperfusion injury. Researchers observed that cerebral ROS generation peaked 1 day after transient middle cerebral artery occlusion (MCAO) in mice, coinciding with an increase in Nrf2, a transcription factor that regulates antioxidant enzymes (Takagi et al., 2014;Yumiko et al., 2017).
Ginkgo biloba leaves extracts can protect against neuronal death caused by ischemia in animal stroke models (Feng et al., 2019). These pharmacological effects are attributed to two major groups of chemical constituents, namely, flavonoids and terpene lactones. Terpene lactones includes ginkgolides A, B, and C, and bilobalide, which are the main components of Ginkgolides ® . In MCAO rats, ginkgolides B treatment could significantly increase the expressions of anti-oxidative stress-related proteins, including superoxide dismutase (SOD). Diterpene ginkgolides (ginkgolide A, ginkgolide B and ginkgolide C) were reported to activate Akt signaling and lead to the nuclear location of Nrf2, which has protective effects against oxidative stress (Liu et al., 2019). Furthermore, in Sprague daw rats with MCAO, pretreatment with bilobalide improved neurological function and increased SOD activity while decreasing infarct volume and brain edema (Jiang et al., 2014).
The immune-mediated inflammatory response that follows AIS is a therapeutic target under current investigation. Previous studies have shown that ginkgolides can reduce inflammation, ameliorate the metabolic disturbances caused by rt-PA. A derivate of ginkgolide B named XQ-1H, suppressed neutrophils infiltration and inflammatory mediators, including matrix metalloproterinase-9 in the ischemic region of the brain (Fang et al., 2015). Down-regulated matrix metalloproterinase-9 expression could reduce extracellular matrix degradation and protect blood brain barrier permeability (BBB) via tight junction in brain endothelial cells (Wei et al., 2013). Finally, preadministration of XQ-1H reduced cerebral infarct size and diminished brain edema after stroke in rats.
Ginkgolide was found to be specific and selective antagonist of platelet activating factor (PAF) (Koch, 2005), which was involved in thrombosis for strong platelet aggregation. Thus, Ginkgolide may enhance the general efficacy of IVT through its antioxidation, anti-inflammatory and antithrombotic mechanisms. But so far, there is no large-scale clinical trial to confirm the general efficacy of Ginkgolide ® in AIS with IVT therapy. Moreover, whether Ginkgolide can increase the risk of hemorrhagic transformation after intravenous thrombolysis in AIS patients is unclear. Thus, we aimed to determine the clinical efficacy and safety of Ginkgolide ® combined with IV rt-PA in AIS.

Study Design and Participants
GIANT was an open label, prospective, multicenter clusterrandomized clinical trial involving 24 hospitals in China (NCT03772847). We enrolled patients who 1) were 18 years or older; 2) were AIS patients who met the criteria of IVT (William et al., 2019); 3) or his/her family member signed an informed consent. We excluded patients who 1) were diagnosed as cerebral arteritis; 2) with baseline alanine aminotransferase or aspartate aminotransferase ≥3 times the upper limit of normal, or baseline serum creatinine ≥1.5 times the upper limit of normal; 3) were allergic to ginkgo drugs, alcohol or glycerol; 4) participated in other clinical trials. The criteria for intravenous thrombolysis was as follows: 1) Inclusion criteria:Clinical diagnosis of ischemic stroke causing measurable neurologic deficit; Onset of symptoms <4.5 h before beginning treatment; Age ≥18 years; 2) Exclusion criteria: Ischemic stroke or severe head trauma in the previous 3 months; Previous intracranial hemorrhage; Intra-axial intracranial neoplasm; Gastrointestinal malignancy; Gastrointestinal/ Urinary hemorrhage in the previous 21 days; Major surgery in the preceding 14 days; Had an arterial puncture of a noncompressible blood vessel in the previous 7 days; Intracranial or intraspinal surgery within the prior 3 months; Symptoms suggestive of subarachnoid hemorrhage; Persistent blood pressure elevation (systolic ≥185 mmHg or diastolic ≥110 mmHg); Glucose levels <50 or >400 mg/dl; Active internal bleeding; Presentation consistent with infective endocarditis; Stroke known or suspected to be associated with aortic arch dissection; Acute bleeding diathesis; Platelet count <100,000/mm 3 ; Current anticoagulant use with an INR >1.7 or PT > 15 s or aPTT >40 s; Therapeutic doses of low molecular weight heparin received within 24 h; Current use of a direct thrombin inhibitor or direct factor Xa inhibitor with evidence of anticoagulant effect by laboratory tests such as aPTT, INR, ECT, TT, or appropriate factor Xa activity assays; Evidence of hemorrhage; Extensive regions of obvious hypodensity consistent with irreversible injury.
The human ethics committee of the Second Affiliated Hospital of Zhejiang University (SAHZU), School of Medicine, approved the trial protocol. The clinical trial was conducted according to the principle expressed in the Declaration of Helsinki. Written consent was obtained from patients or their relatives.

Randomization
The randomization was conducted by using a computer generating randomization sequence where twenty-four hospitals were assigned to the Ginkgolide intervention or control group randomly. Data on all thrombolytic patients in both groups were consecutively recorded in a secure, purposebuilt web-based data entry system.

Interventions
Patients in hospitals which were allocated to the treatment arm received rt-PA (0.9 mg/kg) and an intravenous infusion of Ginkgolide ® (10 ml dissolved in a vehicle containing 250 ml normal saline, once a day, continuous intravenous injection for at least 7 days). The recommended course of treatment is 14 days, so our study requires the intervention group to take medication for at least 7 days. Ginkgolide ® was infused intravenously within 24 h after the initiation of alteplase, and the researcher should record the time from thrombolysis to Ginkgolide ® use. Patients in hospital which were allocated to the control arm received rt-PA and 250 ml normal saline combined standard-of-care therapy following current clinical guidelines. Patients were followed at 7 and 90 days.

Ginkgolide ® was obtained from Chengdu Baiyu
Pharmaceutical Company Limited (each 2 ml per vial, containing terpene lactone 10 mg, batch: No.13110002). Intravenous rt-PA treatment was initiated at a standard dose and regimen (0.9 mg/kg, initial bolus of 10% of the final dose and the remaining dose as an intravenous infusion lasting 60 min) following current clinical guidelines. When a patient met all the inclusion/exclusion criteria and signed the informed consent, Ginkgolide ® infusion was initiated within 24 h after starting the infusion of rt-PA treatment.

Outcome Measures
The primary outcome was the proportion of patients with modified Rankin scale (mRS) ≤2 at 90 days. A structured modified Rankin Score at 90 days of AIS patients was followed up with telephone questionnaires by external clinical evaluators who were blinded to the patients' clinical data. The telephone questionnaire had been validated and was used in previous trial (Collaboration, 2019). The process of telephone assessment was recorded and could be reviewed at any time. Secondary outcomes included National Institute of Health Stroke Scale (NIHSS) scores at 24 h; early neurological improvement (ENI), which was defined as (baseline NIHSS-NIHSS at 7 days)/baseline NIHSS*100%≥18% at 7 days. NIHSS scores were performed by staffs who were not aware of treatment allocation. The mRS scale at 90 days was also followed up with telephone questionnaires by external clinical evaluators who were blinded to the patients' clinical data. The safety outcomes included any intracranial hemorrhage transformation and symptomatic intracranial hemorrhage on the 7-day follow-up. CT scan was performed within 24 h and on 7 ± 1th day after thrombolysis for assessment of hemorrhage, and additional images might be performed in the case of clinical worsening or at the discretion of the treating physicians. Hemorrhagic transformation was classified into hemorrhagic infarction (HI) and parenchymal hemorrhage (PH). An intracerebral hemorrhage was defined as symptomatic intracranial hemorrhage (sICH) if the patient had clinical deterioration causing an increase of NIHSS ≥4 points and if the hemorrhage was likely to be the cause of the clinical deterioration (Hacke et al., 1998).

Sample Size
A pre-randomization survey at participating clusters was conducted. According to previous study, the neurological prognosis was increased 21.1% after the treatment of Ginkgolide. Therefore, a total of 894 patients at 14 hospitals (considering a median of 80 AIS patients treated with rt-PA per hospital) would be required to detect a 21% improvement in AIS patients treated with Ginkgolide combined rt-PA (Yuan and Guo, 2017), with 90% power, 5% significance level, and an intra-cluster correlation coefficient (ICC) of 0.05. Taking into account an estimated 20% rate of non-assessable patients, each arm was required to enroll 560 patients. The sample size calculation formula is as follows (Nijders and Bosker, 1999):

Statistical Analysis
We retrieved demographic and clinical data, the vascular risk factors, time interval from stroke onset to reperfusion therapy (ONT), baseline NIHSS, 24-hour NIHSS and 7-day NIHSS. Clinical outcome at 90 days was assessed with mRS score and dichotomized into good outcome (0-2) and poor outcome (3-6). Full analysis set analyses were conducted. Per-protocol set (PPS) analyses were conducted: for these analyses we only included completers who received therapy at least 7 days and didn't experience PH transformation within 24 h after thrombolysis. Our data analyses focused on the predefined primary and secondary outcomes of the trial in our preregistration (NCT03772847). Fisher's exact test was used to compare the dichotomous variables between groups, while independent samples two-tailed t-test or Mann-Whitney U test was used for the continuous variables, depending on the normality of the distribution. Intra-cluster correlation coefficients (ICC) were calculated using the correlation-based estimation methods for categorical outcomes. To statistically analyze whether there were differences in primary/secondary outcome and safety outcomes between two groups, binary logistic regression analysis was conducted.
Since several baseline factors showed significant differences, we further created a cohort at a 1:1 ratio using propensity scorematching techniques. The use of propensity score analyses balanced the distribution of covariates between treatment and control groups and therefore minimized the influence of potential bias. The resulting propensity score for the treatment of Ginkgolide ® included the following 6 variables: age, sex, baseline NIHSS, history of smoking, hypertension, atrial fibrillation. An additional conditional logistic regression was done for primary outcome and safety outcomes by adjusting baseline NIHSS. Odds ratios (OR), 95% confidence intervals (CI), and p values were calculated. All tests were two-sided, and statistical significance was set at a probability value of <0.05. All statistical analyses were performed with SPSS 20.0, SAS 9.4 and R 4.0.1 package.

Hospital and Patients' Characteristics
Twenty-four hospitals were involved in the trial, but 4 hospitals in control group withdrew at the beginning of the study period. 1189 patients fulfilled the inclusion/exclusion criterion. We excluded 29 patients in the control group and 5 patients in the intervention group because of PH transformation within 24-hour after IV alteplase. We excluded 42 patients in the intervention group because they did not receive treatment for at least 7 days. Finally, 1113 patients were enrolled in the PPS analysis. Of these, 513 were in the intervention group and 600 were in the control group. Study design and timeframe including number of enrolled cases are provided in Figure 1.
The median age was 69 years (mean 69 ± 12 years, range 60-78 years), 452 (40.6%) patients were women. The median baseline NIHSS score was 5 (IQR 3-10). The median onset to IVT was 153 min (IQR 108-203 min). The median time from thrombolysis to Ginkgolide use was 115 min (IQR 15-961 min). A total of 758/1050 (72.2%) patients experienced good outcome. Good outcome was achieved in 78.6% patients in the Ginkgolide group and 66.7% in the control group. Follow-up scans after treatment revealed hemorrhage transformation in 66/844 (7.8%) patients, and sICH was observed in 12/844 (1.4%) patients. Baseline characteristics are shown in Table 1. Results of full analysis set analysis are shown in Supplementary Tables S1, S2.

Propensity-Matched Analysis
Propensity score analysis, balanced for age, gender, baseline NIHSS, history of smoking, hypertension, diabetes mellitus and atrial fibrillation, identified 404 matched patient pairs for outcome of "good outcome at 90 days." As  Table 3). No significant difference in safety outcome of hemorrhage transformation was seen between the 2 matched cohorts ( Table 3).

DISCUSSION
This cluster-randomized trial showed that Ginkgolide ® was effective in improving neurological deficit after rtPA therapy in AIS patients. Additionally, the safety data analysis demonstrated that Ginkgolide ® did not increase the incidence of hemorrhage transformation events.
Although mechanical thrombectomy has recently been established as the standard of care for selected patients with large vessel occlusions, less than 10% of all stroke patients are currently eligible for mechanical thrombectomy based on current guidelines. In this regard, intravenous thrombolysis with alteplase remains a viable treatment for the majority of AIS patients in many centers. A number of experimental studies showed the neuroprotective efficacy of Ginkgolide, which can inhibit the platelet aggregation and increase vascular recanalization in AIS patients (Feng et al., 2019;Dong et al., 2021). Ginkgolide played a role as an inhabitation of PAF receptor, which was induced by ischemic stroke (Joseph et al., 1989). The reduction in PAF and its pathway were reportedly helpful to reduce the volume of infarction in acute phase (Oberpichler et al., 1990). A recently clinical trial also confirmed that Ginkgolide helped in decreasing accumulation of PAF after ischemic stroke, which might be one of the mechanisms in reducing stroke recurrence (Dong et al., 2021). Both Ginkgo biloba extract and its constituent ginkgolide were proved effectively attenuating the rtPA-induced disturbances in neurotransmitter, amino acid, energy, lipid, and nucleotide metabolisms (Pietri et al., 1997;Huang et al., 2012;Li et al., 2013;Chen et al., 2018;Feng et al., 2019;Liu et al., 2019). Chen et al. showed that rtPA upregulated the production of glutamic acid, aspartic acid, N-acetyl-l-aspartic acid, and glutamine. Although both diterpene ginkgolide and ginkgo biloba extract ameliorated the upregulation of aspartic acid and glutamine, diterpene ginkgolide also ameliorated the upregulation of glutamic acid and N-acetyl-l-aspartic acid (Chen et al., 2018). Thus, a This cohot was created at a 1:1 ratio using propensity score-matching techniques for primary outcome of "good outcome at 90 days". Frontiers in Pharmacology | www.frontiersin.org December 2021 | Volume 12 | Article 792136 5 diterpene ginkgolide may exert its neuroprotective effects by reducing the excess production of glutamate and aspartate excitotoxicity, while ginkgo biloba extract may partially ameliorate the excitotoxicity induced by rtPA. But so far, there have been few clinical trials of Ginkgolide. GIANT attained more encouraging results than previous trials because only patients that received thrombolytic therapy were allowed in this study. To the best of our knowledge, this was the largest study to address the management of Ginkgolide ® within the first 24 h after IVT.
In our study, 66.7% of rt-PA-treated patients in the control group had good outcome after 3 months, which was in accordance to results in the Thrombolysis Implementation and Monitor of Acute Ischemic Stroke in China (Zhou et al., 2020). In our study, the degree of improvement of the neurological impairment was more pronounced in the Ginkgolide ® combined with IVT, compared with the control group, indicating that early use of Ginkgolide ® within 24 h after IVT might improve the neurological function of AIS patients. This result was consistent with those of previous studies that showed ginkgolide B and bilobalide might provide neuroprotective effects against rt-PA-induced toxicity.
The antioxidant effects of Ginkgolide ® could have contributed to the clinical benefits reported in the trial.
Researchers found ginkgolide B reduced reactive oxygen species and restored cerebral blood flow in hyperglycemic rats (Huang et al., 2012). Of note, ginkgolide B treatment could significantly increase the expressions of anti-oxidative stress-related proteins, such as Nrf2. Ginkgolide B was also believed to interfere with the production of free radicals after ischemia (Pietri et al., 1997). These characteristics may support the Ginkgolide ® as an antioxidant in AIS patients within the first 24 h after IVT. Furthermore, ginkgolide B could also protect brain from endoplasmic reticulum (ER) stress, which was also an essential signaling event in the progression of brain ischemic/reperfusion injury. In a cell model, preincubation with ginkgolide B could attenuate bupivacaine-induced ER stress and cell apoptosis (Li et al., 2013). Another important component of Ginkgolide ® , bilobalide, can also reduce ER stress by increasing the expression of catalase and glutathione (Lu et al., 2016).
Hence, the early use of Ginkgolide ® after IVT may prevent further oxidative stress injury and ER stress and thereby improve the functional outcome.
The N-methyl-D-aspartate receptor also played a pivotal role in the process of glutamate-induced excitotoxicity in stroke (Wu and Tymianski, 2018). Intravenous rt-PA can potentiate excitotoxic lesions and lead to neuronal death induced by NMDA (Nicole et al., 2001). Administration of Ginkgo biloba extract effectively inhibited NMDA-receptor and ameliorated  metabolic disturbances induced by rt-PA (Chen et al., 2018). Moreover, bilobalide enhanced cell viabilities, inhibited apoptosis, and attenuated mitochondrial membrane potential depolarization (Shi et al., 2010;Shi et al., 2011). By triggering various pathways, Ginkgolide ® seemed to interrupt the development of pathological processes that lead to ischemic/ reperfusion injury after rtPA therapy.
During recent years, several cases of hemorrhage including subdural hematoma (Rowin and Lewis, 1996), subarachnoid hemorrhage (Vale, 1998), intracerebral hemorrhage (Matthews, 1998), have been reported to occur in coincidence with the use of Ginkgo products and those observations have generally been explained by the platelet-activating factor (PAF)-antagonistic action of ginkgolides. However, in this study, ultra-early administration of Ginkgolide ® after IVT did not involve a higher risk of hemorrhage transformation or sICH. Indeed, results from different studies consistently indicated that Ginkgo does not significantly affect hemostasis nor the safety of co-administered aspirin, warfarin and other antiplatelet drugs (Bone, 2008). E Koch confirmed that induction of aggregation of human platelets by PAF requires higher concentration, which were generally more than 100 times higher as the peak plasma values measured after oral intake ginkgo biloba extract at recommended doses (Koch, 2005). Therefore, the likelihood of hemorrhage transformation due to PAF is very low, and those case reports might be coincidences. In vitro multicellular network model, pretreatment with Ginkgo biloba extract or ginkgolide B enhanced the trans-endothelial electrical resistance of capillary endothelial monolayers, reduced the endothelial permeability coefficients for sodium fluorescein, and increased the expression levels of tight junction proteins, namely, ZO-1 and occludin, in endothelial cells (Yang et al., 2017). Results demonstrated the preventive effects of Ginkgo biloba extract on neuronal cell death and enhancement of the function of brain capillary endothelial monolayers after oxygen-glucose deprivation/reoxygenation injury in vitro. Ginkgolides ® are mainly composed of ginkgo diterpene lactones (ginkgolide A, B, and C) and bilobalide. Ginkgo diterpene lactone mainly plays a role in inhibiting platelet aggregation caused by PAF and inhibiting the production of inflammatory molecules during ischemia-reperfusion, while bilobalide mainly functions to maintain the integrity of vascular endothelial cells and promote vascular endothelial proliferation. Our result also showed the use of Ginkgolide ® was not associated with hemorrhage transformation after adjusting baseline NIHSS, indicating that ginkgolides could not increase hemorrhage transformation in AIS patients receiving IV rt-PA, indicating that it is safe and effective to use Ginkgolides ® within 24 h after intravenous thrombolysis. It may be due to the anti-platelet aggregation and anti-inflammation of ginkgolides, while bilobalide protects blood brain barrier permeability, which may further diminish the risk of hemorrhage transformation.
Limitations include biased baseline characters such as baseline NIHSS, hypertension and atrial fibrillation, although after adjusting for baseline NIHSS and these comorbidities, intervention with Ginkgolide ® was still significantly associated with 90-day mRS. Secondly, the underlying mechanism of Ginkgolide improving neurological deficits was not revealed in our study, which need further imaging or lab markers. Thirdly, we analyzed patients mostly in the Yangtze River Delta, which may introduce geographic bias.

CONCLUSION
In summary, the present study suggests that Ginkgolide ® use in patients within the first 24 h after IVT was safe and could have a favorable impact on functional outcome. Ginkgolide ® therapy might be the treatment of choice for patients at the first 24 h after IVT. Confirmation of these findings in a larger randomized trial is needed.